RAF1 and melanoma: CCT018159 displayed a number of similar activities compared with geldanamycin and geldanamycin derivatives including induction of HSP70 expression [111], depletion of melanoma-related oncoproteins such as BRAFV600E, CRAF, CDK4 (cyclin-dependent kinase 4), ERBB2 (receptor tyrosine protein kinase ERBB2) [111], attenuation of ERK1/2 activity [87, 111] and upregulation of genes involved in melanoma cell differentiation [87].